Background. Chronic stress caused by military conflicts and prolonged security threats in Ukraine and Israel has led to an increased demand for sedative medicinal products. Under these conditions, the analysis of the pharmaceutical market structure and the accessibility of such medicines becomes particularly relevant. Objective. To conduct a comparative analysis of the assortment, origin, and price accessibility of sedative medicinal products on the pharmaceutical markets of Ukraine and Israel as of 2025. Methods. The study was based on data obtained from the State Register of Medicinal Products of Ukraine, the Drug Registry of the Ministry of Health of Israel, and the analytical system Pharmstandard developed by the Morion company. The study employed the ATC classification system, as well as comparative and marketing analysis methods. Results. The results demonstrated that the pharmaceutical market of Ukraine is characterized by a broader assortment of sedative medicinal products (147 trade names within five ATC subgroups), approximately 75–80% of which are produced by domestic manufacturers. In contrast, the Israeli market is characterized by stricter regulation of prescription dispensing and a relatively smaller assortment of over-the-counter herbal medicines. In Ukraine, the availability of sedative medicines is mainly ensured by their relatively low price, whereas in Israel accessibility is largely supported by the national health insurance system and reimbursement mechanisms for medicinal products (Health Basket, Sal HaBriut). Conclusions. The pharmaceutical markets of sedative medicines in Ukraine and Israel differ in terms of the structure of the assortment and mechanisms ensuring medicine accessibility. In Ukraine, accessibility is largely determined by a wide range of herbal medicines and their relatively low price, while in Israel the key factor is the functioning of the health insurance system. The findings of this study may be useful for improving pharmaceutical supply mechanisms and developing reimbursement policies aimed at increasing the accessibility of sedative medicines for the population.
Loading....